Onyx Biotec Ltd IPO

Onyx Biotec Ltd IPO

Pharmaceuticals

sme

Bidding period

13 Nov 2024 - 18 Nov 2024

Bid price

₹61.00 - ₹61.00

Listing on

NSE-SME

Listing date

22 Nov 2024

Lot size

2000 shares

Issue size

₹29.34 crore


Minimum investment

₹1,22,000.00 / 1 lot

Maximum investment

₹1,22,000.00 / 1 lot

Bidding closed on 18 Nov 2024

EXPLORE IPOs
EXPLORE IPOs

Onyx Biotec Ltd IPO dates

IPO opening date

13 Nov 2024

IPO end date

18 Nov 2024

Allotment date

19 Nov 2024

Initiation of refunds

20 Nov 2024

Credit of shares to demat

20 Nov 2024

IPO listing date

22 Nov 2024

Onyx Biotec Ltd IPO financials

Particulars

For the period ending in March 2024 (in ₹ million)

Total assets ₹74.14
Total liabilities ₹74.14
Total expenditure ₹49.82
Total revenue ₹53.87
Profit after tax ₹3.03
EBITDA ₹8.41
Adjusted EBITDA ₹0.00

Onyx Biotec Ltd shareholder pattern

Pre-issue Post-issue
Promoter group 88.6 65.1
Public group 11.4 34.9

Onyx Biotec Ltd strengths and risks

Information currently unavailable

  • One of the prominent contract manufacturers in sterile manufacturing.

  • Quality Assurance and Quality Control of our products.

  • Strong, cordial & long-term relationship with our Marque Clientele.

  • Cost effective production and timely fulfilment of orders.

  • Well experienced management team with proven project management and implementation skills.

  • Its manufacturing units are concentrated in Solan, Himachal Pradesh, and the company is exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.

  • Any slowdown or shutdown in its manufacturing operations could have an adverse effect on its business, results of operations, financial condition and cash flows.

  • Any manufacturing or quality control concerns or its inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by its clients and distributors, which could have an adverse effect on its business, results of operations, financial condition and cash flows.

  • Its manufacturing units are subject to periodic inspections and audits by regulatory authorities and clients. The company may be subject to regulatory action which may damage its reputation leading to an adverse effect on its business, results of operations, financial condition and cash flows.

  • The company relies on domestic and international third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.

  • Its business is dependent on sale of products to a limited number of clients for a significant portion of its revenues. The loss of one or more such clients or the deterioration of their financial condition or prospects could adversely affect its business, results of operations and financial condition.

  • The Company is reliant on the demand from the pharmaceutical industry. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.

  • The commercial success of its products depends to a large extent on the success of the products of its customers. If the demand for the products of the company's customers declines, it could have a material adverse effect on its business, financial condition and results of operations.

  • Its may faces several risks associated with the proposed expansion of the company's manufacturing facilities, which could hamper its growth, prospects, cash flows and business and financial condition.

  • Its cannot assure you that the proposed expansion of the company's manufacturing units will become operational as scheduled, or at all, or operates as efficiently as planned. If the company is unable to commission its new facilities in a timely manner or without cost overruns, it may adversely affect its business, results of operations and financial condition.

How to check the allotment status of the Onyx Biotec Ltd IPO?

To check the IPO allotment status, follow these steps:

 

  1. Visit the official website of the IPO’s registrar.
  2. Go to the IPO allotment status page.
  3. Select the ‘Onyx Biotec Ltd’ from the list of available IPOs.
  4. Enter your PAN, Demat ID, or application number.
  5. Click on ‘Submit’ or ‘Check Status’ to view your allotment details.

Alternatively, you can also check the allotment status on stock exchange websites such as the NSE or BSE.

To check the IPO allotment status, follow these steps:

 

  1. Visit the official website of the IPO’s registrar.
  2. Go to the IPO allotment status page.
  3. Select the ‘Onyx Biotec Ltd’ from the list of available IPOs.
  4. Enter your PAN, Demat ID, or application number.
  5. Click on ‘Submit’ or ‘Check Status’ to view your allotment details.

Alternatively, you can also check the allotment status on stock exchange websites such as the NSE or BSE.

Read more Read less

Onyx Biotec Ltd IPO registrar

Mas Services Limited

Phone number 91 112 6387281/83,114 1320335
E-mail ID investor@masserv.com
Website www.masserv.com

Onyx Biotec Ltd IPO reservation

QIB shares offered

9,12,000 (18.96%)

NII (HNI) shares offered

6,88,000 (14.3%)

Retail shares offered

16,00,000 (33.26%)

Anchor investor shares offered

13,66,000 (28.4%)

Total shares offered

48,10,000

Total shares with anchor investor

48,10,000

Onyx Biotec Ltd IPO lead manager

  • Horizon Management Pvt Ltd

Explore other IPOs

How to apply for an IPO with Bajaj Broking?

adafafds
 
 
  • Log in to the Bajaj Broking trading platform and select ‘IPO’ from the menu.
  • Browse the list of open IPOs and click ‘Apply’ for your chosen IPO.
  • Enter the quantity and your UPI ID.
  • Submit your application—and you're done!

Frequently asked questions

What is the listing date for the Onyx Biotec Ltd IPO?

The listing date for the Onyx Biotec Ltd IPO is 22 Nov 2024.

What is the issue size of Onyx Biotec Ltd IPO?

The issue size of the Onyx Biotec Ltd IPO is ₹29.34 cr.

What is the minimum lot size needed for Onyx Biotec Ltd IPO?

The minimum lot size for Onyx Biotec Ltd IPO is 2000

When does the Onyx Biotec Ltd open and close?

Onyx Biotec Ltd IPO is open from 13 Nov 2024 to 18 Nov 2024.

How can I apply for the Onyx Biotec Ltd IPO?

To apply for the Onyx Biotec Ltd, follow the steps given below:

  • Log in to your Bajaj Broking trading account and navigate to the current IPOs section.
  • Browse the list of open IPOs and click ‘Apply’ for your chosen PO.
  • Enter the quantity and your UPI ID. You will receive a mandate notification to block funds in your UPI app.
SHOW MORE SHOW LESS

Disclaimer

*Disclaimer for Bajaj Finance Limited (‘BFL’):

Stock trading business is carried by Bajaj Financial Securities Limited ("BFSL"), a broker and Depository Participant registered with Securities Exchange Board of India and offers various products/services related to Securities market (Securities market products/services). BFL merely facilitates display of data shared by BFSL on its webpage/mobile application. Such data received from BFSL, or any of its service providers is on “as is” basis. BFL does not make any representation or warranty, express or implied, regarding accuracy, completeness of such data displayed herein.

When you opt to avail the Securities market products/services of BFSL by clicking on the BFSL weblink/mobile app, you will be redirected to BFSL's web page/mobile app for initiation and completion of the transaction. You are supposed to exercise independent diligence by reading all the related documents carefully before deciding to invest in Securities market Products/services.

BFL is a Non-Banking Financial Company carrying the business of acceptance of deposits and providing lending solutions to Retail and Corporate customers. BFL does not offer nor advice on Securities market products/services and shall not be liable or responsible for any of your investment decision."

**Disclaimer: For Bajaj Financial Securities Limited

Investments in securities market are subject to market risk, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. All leveraged intraday positions will be squared off the same day. There is no restriction on withdrawal of unutilised margin amount. Trade Recommendations are research-calls provided under the SEBI Research Analyst guidelines.
Visit https://www.bajajbroking.in/disclaimer for complete disclaimer.

Securities market Products/services are made available only at the discretion of BFSL and subject to the individual contractual terms and conditions of the respective Securities market products/services. You shall be the sole owner of any decision to invest in any BFSL's Securities market products/services.

Securities market products/services may be withdrawn or amended at any time by BFSL without notice and your recourse in such case would be directly to reach out BFSL at connect@bajajfinserv.in or 1800 833 8888.

Powered by Bajaj Financial Securities Limited (Bajaj Broking)